Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy

The American Journal of Cardiology
Myriam AmsallemPatrick Henry

Abstract

Aspirin is the key treatment in the secondary prevention of atherothrombosis. Interindividual variability of response has been linked to a higher risk for ischemic events. The aim of this study was to identify clinical and biologic factors predicting high on-aspirin platelet reactivity (HPR) in a high-risk, "real-world" population of vascular patients. All platelet testing performed from 2011 to 2013 in consecutive patients receiving long-term treatment with aspirin for coronary or cerebrovascular disease was retrospectively analyzed. Indications for platelet testing were recurrent ischemic events or high-risk angioplasty. HPR was defined as aggregation intensity≥20% using light-transmission aggregometry with arachidonic acid 0.5 mg/ml. Collagen-epinephrine platelet function analysis was also performed (threshold<165 seconds). Cardiovascular risk factors, usual biologic parameters, and antiplatelet treatment were recorded. A total of 1,508 patients were included (mean age 63 years, 71% men, 23% with diabetes). Antiplatelet treatment was aspirin alone in 333 patients and dual-antiplatelet therapy in 1,175 patients. HPR was found in 11.1% of patients. In multivariate analysis, independent predictive factors of HPR on light-transm...Continue Reading

References

Dec 1, 1985·Circulation·C PatronoL Forni
Oct 20, 2010·Journal of Thrombosis and Haemostasis : JTH·E L GroveS D Kristensen
Oct 17, 2012·American Heart Journal·Jean-Guillaume DillingerPatrick Henry
Sep 27, 2013·European Heart Journal·Dániel AradiUNKNOWN Working Group on Thrombosis of the European Society of Cardiology
Oct 5, 2013·Blood·Fahumiya Samad, Wolfram Ruf

❮ Previous
Next ❯

Citations

Jan 8, 2016·Journal of Thrombosis and Thrombolysis·Joonseok Kim, Richard C Becker
Aug 18, 2016·European Heart Journal. Cardiovascular Pharmacotherapy·Stéphane Manzo-SilbermanPhilippe Gabriel Steg
Feb 15, 2019·Pediatric Blood & Cancer·Alexander A BoucherLori Luchtman-Jones
Nov 13, 2018·American Journal of Therapeutics·Elena BobescuLuigi G Marceanu
May 9, 2019·Journal of Thrombosis and Thrombolysis·Monica VerdoiaUNKNOWN Novara Atherosclerosis Study Group (NAS)
Jul 11, 2018·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jeffrey S Berger
Oct 12, 2018·Journal of Veterinary Pharmacology and Therapeutics·Jillian M HainesMichael H Court

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.